About StemlineTherapeutics (NASDAQ:STML)
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311
Debt
Debt-to-Equity RatioN/A
Current Ratio2.63%
Quick Ratio2.63%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$900,000.00
Price / Sales570.63
Cash FlowN/A
Price / CashN/A
Book Value$1.62 per share
Price / Book10.49
Profitability
EPS (Most Recent Fiscal Year)($2.94)
Net Income$-67,820,000.00
Net Margins-4,689.63%
Return on Equity-94.70%
Return on Assets-77.89%
Miscellaneous
Employees37
Outstanding Shares30,210,000
StemlineTherapeutics (NASDAQ:STML) Frequently Asked Questions
What is StemlineTherapeutics' stock symbol?
StemlineTherapeutics trades on the NASDAQ under the ticker symbol "STML."
How were StemlineTherapeutics' earnings last quarter?
StemlineTherapeutics Inc. (NASDAQ:STML) posted its quarterly earnings results on Friday, March, 16th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.26. StemlineTherapeutics had a negative return on equity of 94.70% and a negative net margin of 4,689.63%. View StemlineTherapeutics' Earnings History.
When is StemlineTherapeutics' next earnings date?
What price target have analysts set for STML?
4 brokerages have issued 1 year target prices for StemlineTherapeutics' stock. Their forecasts range from $16.00 to $40.00. On average, they anticipate StemlineTherapeutics' share price to reach $31.3333 in the next year. View Analyst Ratings for StemlineTherapeutics.
What are Wall Street analysts saying about StemlineTherapeutics stock?
Here are some recent quotes from research analysts about StemlineTherapeutics stock:
- 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (3/23/2018)
- 2. HC Wainwright analysts commented, "Bio-Path reported 1Q17 with operating expenses of $2M which were offset by a change in non-cash warrant liability for a net loss of $0.4M. Bio-Path ended the period with $7.1M in cash, sufficient runway to the end of the year." (5/15/2017)
- 3. Cowen Inc analysts commented, "STML reported 1Q17 financials and provided a pipeline update." (5/12/2017)
Are investors shorting StemlineTherapeutics?
StemlineTherapeutics saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 2,316,217 shares, an increase of 46.8% from the March 15th total of 1,577,965 shares. Based on an average trading volume of 586,094 shares, the short-interest ratio is presently 4.0 days. Approximately 8.5% of the shares of the company are short sold.
Who are some of StemlineTherapeutics' key competitors?
Some companies that are related to StemlineTherapeutics include Corcept Therapeutics (CORT), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Insmed (INSM), Arena Pharmaceuticals (ARNA), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), MyoKardia (MYOK), Akcea Therapeutics (AKCA), Spectrum Pharmaceuticals (SPPI), Cambrex (CBM), Phibro Animal Health (PAHC), OPKO Health (OPK), Enanta Pharmaceuticals (ENTA) and Akorn (AKRX).
Who are StemlineTherapeutics' key executives?
StemlineTherapeutics' management team includes the folowing people:
- Dr. Ivan Bergstein, Founder, Chairman, CEO & Pres (Age 52)
- Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 58)
- Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 53)
- Dr. Eric K. Rowinsky, Consultant (Age 61)
Has StemlineTherapeutics been receiving favorable news coverage?
News stories about STML stock have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. StemlineTherapeutics earned a news impact score of 0.11 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 47.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of StemlineTherapeutics?
Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is StemlineTherapeutics' stock price today?
One share of STML stock can currently be purchased for approximately $17.00.
How big of a company is StemlineTherapeutics?
StemlineTherapeutics has a market capitalization of $509.04 million and generates $900,000.00 in revenue each year. The biopharmaceutical company earns $-67,820,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. StemlineTherapeutics employs 37 workers across the globe.
How can I contact StemlineTherapeutics?
StemlineTherapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]
MarketBeat Community Rating for StemlineTherapeutics (STML)
MarketBeat's community ratings are surveys of what our community members think about StemlineTherapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
StemlineTherapeutics (NASDAQ:STML) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for StemlineTherapeutics in the last 12 months. Their average twelve-month price target is $31.3333, suggesting that the stock has a possible upside of 84.31%. The high price target for STML is $40.00 and the low price target for STML is $16.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $31.3333 | $31.3333 | $33.75 | $32.60 |
| Price Target Upside: | 84.31% upside | 123.01% upside | 115.65% upside | 232.65% upside |
StemlineTherapeutics (NASDAQ:STML) Consensus Price Target History
StemlineTherapeutics (NASDAQ:STML) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
StemlineTherapeutics (NASDAQ:STML) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
StemlineTherapeutics (NASDAQ STML) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 49.83%
StemlineTherapeutics (NASDAQ STML) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/13/2018 | Kenneth Hoberman | COO | Sell | 29,987 | $17.14 | $513,977.18 | |  |
| 3/12/2018 | David Gionco | Insider | Sell | 9,183 | $17.38 | $159,600.54 | | |
| 3/12/2018 | Ivan Bergstein | CEO | Sell | 37,857 | $17.34 | $656,440.38 | | |
| 3/7/2018 | David Gionco | Insider | Sell | 1,413 | $16.56 | $23,399.28 | | |
| 3/7/2018 | Ivan Bergstein | CEO | Sell | 6,797 | $16.56 | $112,558.32 | | |
| 3/7/2018 | Kenneth Hoberman | COO | Sell | 3,027 | $16.55 | $50,096.85 | | |
| 2/27/2018 | David Gionco | Insider | Sell | 8,984 | $17.43 | $156,591.12 | | |
| 2/27/2018 | Ivan Bergstein | CEO | Sell | 24,183 | $17.42 | $421,267.86 | | |
| 2/27/2018 | Kenneth Hoberman | COO | Sell | 11,026 | $17.43 | $192,183.18 | | |
| 2/15/2018 | Ivan Bergstein | CEO | Sell | 3,820 | $15.80 | $60,356.00 | | |
| 2/15/2018 | Kenneth Hoberman | COO | Sell | 1,851 | $15.67 | $29,005.17 | | |
| 1/17/2018 | David Gionco | Insider | Sell | 4,250 | $13.43 | $57,077.50 | | |
| 1/8/2018 | Kenneth Hoberman | COO | Sell | 14,040 | $13.93 | $195,577.20 | | |
| 12/18/2017 | Kenneth Hoberman | COO | Sell | 11,983 | $14.18 | $169,918.94 | | |
| 12/15/2017 | Kenneth Hoberman | COO | Sell | 11,943 | $14.18 | $169,351.74 | | |
| 2/28/2017 | David Gionco | Insider | Sell | 6,486 | $6.99 | $45,337.14 | | |
| 2/28/2017 | Ivan Bergstein | CEO | Sell | 17,980 | $6.99 | $125,680.20 | | |
| 2/28/2017 | Kenneth Hoberman | COO | Sell | 8,027 | $6.99 | $56,108.73 | | |
| 2/27/2017 | David Gionco | CAO | Sell | 3,500 | $6.97 | $24,395.00 | | |
| 2/27/2017 | Ivan Bergstein | CEO | Sell | 7,500 | $6.97 | $52,275.00 | | |
| 2/27/2017 | Kenneth Hoberman | COO | Sell | 4,000 | $6.97 | $27,880.00 | | |
| 2/16/2017 | Ivan Bergstein | CEO | Sell | 3,652 | $6.42 | $23,445.84 | | |
| 2/16/2017 | Kenneth Hoberman | COO | Sell | 1,508 | $6.42 | $9,681.36 | | |
| 1/19/2017 | David Gionco | Insider | Sell | 3,593 | $11.46 | $41,175.78 | | |
| 1/10/2017 | Kenneth Hoberman | COO | Sell | 9,110 | $13.82 | $125,900.20 | | |
| 3/8/2016 | David Gionco | CAO | Sell | 1,148 | $5.32 | $6,107.36 | 106,467 | |
| 3/8/2016 | Ivan Bergstein | CEO | Sell | 5,537 | $5.34 | $29,567.58 | 1,846,128 | |
| 3/8/2016 | Kenneth Hoberman | COO | Sell | 2,412 | $5.34 | $12,880.08 | 297,392 | |
| 2/17/2016 | Ivan Bergstein | CEO | Sell | 3,244 | $4.46 | $14,468.24 | | |
| 2/17/2016 | Kenneth Hoberman | COO | Sell | 1,503 | $4.54 | $6,823.62 | | |
| 1/20/2016 | David Gionco | CAO | Sell | 3,217 | $4.82 | $15,505.94 | 35,244 | |
| 11/30/2015 | Ivan Bergstein | CEO | Sell | 12,235 | $8.20 | $100,327.00 | 1,926,826 | |
| 4/27/2015 | Eric K Rowinsky | Insider | Sell | 10,824 | $15.77 | $170,694.48 | | |
| 3/19/2015 | Kenneth Hoberman | COO | Sell | 17,307 | $16.43 | $284,354.01 | | |
| 1/20/2015 | David Gionco | CAO | Sell | 3,311 | $14.22 | $47,082.42 | | |
| 11/26/2014 | Ivan Bergstein | CEO | Sell | 11,974 | $14.40 | $172,425.60 | | |
| 9/3/2014 | Ivan Bergstein | CEO | Buy | 2,000 | $11.05 | $22,100.00 | | |
| 9/2/2014 | Kenneth Hoberman | COO | Buy | 2,000 | $10.99 | $21,980.00 | | |
| 9/2/2014 | Kenneth J Zuerblis | Director | Buy | 1,000 | $11.14 | $11,140.00 | | |
| 5/30/2013 | Kenneth J Zuerblis | Director | Buy | 3,000 | $16.01 | $48,030.00 | | |
(Data available from 1/1/2013 forward)
StemlineTherapeutics (NASDAQ STML) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks Investment Research Downgrades StemlineTherapeutics (STML) to Sell
www.americanbankingnews.com - April 17 at 6:29 PM |
 | Form 8-K STEMLINE THERAPEUTICS For: Apr 16
www.streetinsider.com - April 17 at 9:07 AM |
| StemlineTherapeutics (STML) Upgraded at BidaskClub
www.americanbankingnews.com - April 16 at 11:29 PM |
 | Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of ...
globenewswire.com - April 16 at 4:58 PM |
 | BRIEF-Stemline Therapeutics Expands Board Of Directors With Appointment Of Darren Cline
www.reuters.com - April 16 at 8:44 AM |
 | Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline
feeds.benzinga.com - April 16 at 7:46 AM |
| StemlineTherapeutics Inc. (STML) Short Interest Up 46.8% in March
www.americanbankingnews.com - April 14 at 2:29 AM |
| StemlineTherapeutics (STML) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - April 12 at 10:45 AM |
| HC Wainwright Reiterates "$34.00" Price Target for StemlineTherapeutics (STML)
www.americanbankingnews.com - April 11 at 11:52 PM |
| ValuEngine Lowers StemlineTherapeutics (STML) to Sell
www.americanbankingnews.com - April 11 at 3:58 PM |
| Zacks: Analysts Expect StemlineTherapeutics Inc. (STML) Will Announce Earnings of -$0.70 Per Share
www.americanbankingnews.com - April 10 at 1:22 PM |
| HC Wainwright Begins Coverage on StemlineTherapeutics (STML)
www.americanbankingnews.com - April 6 at 10:47 AM |
| Stemline Therapeutics (STML) Begins Rolling BLA Submission for SL-401
www.streetinsider.com - April 5 at 10:51 AM |
 | Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401
finance.yahoo.com - April 5 at 10:51 AM |
| StemlineTherapeutics Inc. (STML) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 5 at 3:24 AM |
| StemlineTherapeutics (STML) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 12:00 AM |
| Stemline Therapeutics (STML) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 30 at 5:40 PM |
| Stemline Therapeutics (STML) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 29 at 6:54 PM |
| Stemline Therapeutics (STML) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM |
| Stemline Therapeutics (STML) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - March 23 at 8:28 PM |
 | Stemline Therapeutics Inc Stock Investors Are Betting, Not Investing
investorplace.com - March 23 at 6:33 PM |
| Stemline Therapeutics (STML) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 23 at 3:07 PM |
| Stemline Therapeutics Inc Forecasted to Earn Q1 2018 Earnings of ($0.72) Per Share (STML)
www.americanbankingnews.com - March 22 at 8:12 AM |
| Stemline Therapeutics (STML) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 21 at 10:36 PM |
| Stemline Therapeutics Inc Expected to Post FY2022 Earnings of $2.29 Per Share (STML)
www.americanbankingnews.com - March 21 at 4:40 PM |
| HC Wainwright Reiterates "$38.00" Price Target for Stemline Therapeutics (STML)
www.americanbankingnews.com - March 19 at 5:02 PM |
| Stemline Therapeutics (STML) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 18 at 4:24 PM |
| Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 18 at 8:46 AM |
| Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 16 at 8:55 AM |
| Stemline Therapeutics reports 4Q loss
finance.yahoo.com - March 16 at 8:55 AM |
| Stemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 29,987 Shares
www.americanbankingnews.com - March 14 at 11:12 PM |
| Stemline Therapeutics Inc (STML) CEO Ivan Bergstein Sells 37,857 Shares
www.americanbankingnews.com - March 14 at 10:41 PM |
| Stemline Therapeutics Inc (STML) Insider Sells $159,600.54 in Stock
www.americanbankingnews.com - March 14 at 10:41 PM |
| Breakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)
finance.yahoo.com - March 14 at 9:23 AM |
| ValuEngine Downgrades Stemline Therapeutics (STML) to Sell
www.americanbankingnews.com - March 13 at 10:19 PM |
| Stemline Therapeutics (STML) Cut to Sell at ValuEngine
www.americanbankingnews.com - March 11 at 9:02 PM |
| Stemline Therapeutics Inc (STML) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 11 at 4:29 AM |
| Kenneth Hoberman Sells 3,027 Shares of Stemline Therapeutics Inc (STML) Stock
www.americanbankingnews.com - March 10 at 4:21 AM |
| Ivan Bergstein Sells 6,797 Shares of Stemline Therapeutics Inc (STML) Stock
www.americanbankingnews.com - March 10 at 4:20 AM |
| Stemline Therapeutics Inc (STML) Insider Sells $23,399.28 in Stock
www.americanbankingnews.com - March 10 at 4:20 AM |
| Stemline Therapeutics (STML) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:50 AM |
| Contrasting Spring Bank Pharmaceuticals (SBPH) and Stemline Therapeutics (STML)
www.americanbankingnews.com - March 2 at 1:39 PM |
| Stemline Therapeutics Inc (STML) CEO Ivan Bergstein Sells 24,183 Shares
www.americanbankingnews.com - March 1 at 12:38 AM |
| Stemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 11,026 Shares
www.americanbankingnews.com - March 1 at 12:38 AM |
| Stemline Therapeutics Inc (STML) Insider David Gionco Sells 8,984 Shares
www.americanbankingnews.com - March 1 at 12:38 AM |
| Kenneth Hoberman Sells 1,851 Shares of Stemline Therapeutics Inc (STML) Stock
www.americanbankingnews.com - February 17 at 12:14 AM |
| Ivan Bergstein Sells 3,820 Shares of Stemline Therapeutics Inc (STML) Stock
www.americanbankingnews.com - February 17 at 12:14 AM |
| Zacks Investment Research Lowers Stemline Therapeutics (STML) to Sell
www.americanbankingnews.com - February 15 at 2:08 PM |
| Stemline Therapeutics Inc (STML) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 14 at 3:34 AM |
| Stemline Therapeutics (STML) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 9 at 1:04 PM |
StemlineTherapeutics (NASDAQ:STML) SEC Filings
This page is loading this company's SEC Filings. Please wait...
StemlineTherapeutics (NASDAQ:STML) Income Statement, Balance Sheet and Cash Flow Statement
StemlineTherapeutics (NASDAQ STML) Stock Chart for Thursday, April, 26, 2018
Loading chart…
